These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 22998583)

  • 21. Anaplastic lymphoma kinase: a glimmer of hope in lung cancer treatment?
    Franco R; Rocco G; Marino FZ; Pirozzi G; Normanno N; Morabito A; Sperlongano P; Stiuso P; Luce A; Botti G; Caraglia M
    Expert Rev Anticancer Ther; 2013 Apr; 13(4):407-20. PubMed ID: 23560836
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of novel anaplastic lymphoma kinase (ALK) inhibitors using a common feature pharmacophore model derived from known ligands crystallized with ALK.
    Xie HZ; Lan H; Pan YL; Zou J; Wang ZR; Li LL; Huang Q; Zhang H; Yang SY
    Chem Biol Drug Des; 2013 Feb; 81(2):175-84. PubMed ID: 23107363
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The emerging role of ALK inhibitors in the treatment of advanced non-small cell lung cancer.
    Galetta D; Rossi A; Pisconti S; Colucci G
    Expert Opin Ther Targets; 2012 Apr; 16 Suppl 2():S45-54. PubMed ID: 22443113
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anaplastic lymphoma kinase inhibitors.
    Crescenzo R; Inghirami G
    Curr Opin Pharmacol; 2015 Aug; 23():39-44. PubMed ID: 26051994
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The ALK gene, an attractive target for inhibitor development.
    Tartari CJ; Scapozza L; Gambacorti-Passerini C
    Curr Top Med Chem; 2011; 11(11):1406-19. PubMed ID: 21513493
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Journey of the ALK-inhibitor CH5424802 to phase II clinical trial.
    Latif M; Saeed A; Kim SH
    Arch Pharm Res; 2013 Sep; 36(9):1051-4. PubMed ID: 23700294
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Virtual screening and further development of novel ALK inhibitors.
    Okamoto M; Kojima H; Saito N; Okabe T; Masuda Y; Furuya T; Nagano T
    Bioorg Med Chem; 2011 May; 19(10):3086-95. PubMed ID: 21515061
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802).
    Kinoshita K; Asoh K; Furuichi N; Ito T; Kawada H; Hara S; Ohwada J; Miyagi T; Kobayashi T; Takanashi K; Tsukaguchi T; Sakamoto H; Tsukuda T; Oikawa N
    Bioorg Med Chem; 2012 Feb; 20(3):1271-80. PubMed ID: 22225917
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A new look at the ALK gene in cancer: copy number gain and amplification.
    Zito Marino F; Rocco G; Morabito A; Mignogna C; Intartaglia M; Liguori G; Botti G; Franco R
    Expert Rev Anticancer Ther; 2016 May; 16(5):493-502. PubMed ID: 26943457
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ALK as a paradigm of oncogenic promiscuity: different mechanisms of activation and different fusion partners drive tumors of different lineages.
    Mariño-Enríquez A; Dal Cin P
    Cancer Genet; 2013 Nov; 206(11):357-73. PubMed ID: 24091028
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors.
    Ceccon M; Mologni L; Bisson W; Scapozza L; Gambacorti-Passerini C
    Mol Cancer Res; 2013 Feb; 11(2):122-32. PubMed ID: 23239810
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An updated patent review of anaplastic lymphoma kinase inhibitors (2018-2022).
    Ma D; Guo M; Zhai X
    Expert Opin Ther Pat; 2023 Apr; 33(4):323-337. PubMed ID: 37208827
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetic/pharmacodynamic modeling of crizotinib for anaplastic lymphoma kinase inhibition and antitumor efficacy in human tumor xenograft mouse models.
    Yamazaki S; Vicini P; Shen Z; Zou HY; Lee J; Li Q; Christensen JG; Smith BJ; Shetty B
    J Pharmacol Exp Ther; 2012 Mar; 340(3):549-57. PubMed ID: 22129595
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S; Djelloul S; Raymond E
    Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Crizotinib in the treatment of non-small-cell lung cancer.
    Forde PM; Rudin CM
    Expert Opin Pharmacother; 2012 Jun; 13(8):1195-201. PubMed ID: 22594847
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.
    O'Bryant CL; Wenger SD; Kim M; Thompson LA
    Ann Pharmacother; 2013 Feb; 47(2):189-97. PubMed ID: 23386065
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New perspectives for targeting therapy in ALK-positive human cancers.
    Zhao S; Li J; Xia Q; Liu K; Dong Z
    Oncogene; 2023 Jun; 42(24):1959-1969. PubMed ID: 37149665
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The anaplastic lymphoma kinase as an oncogene in solid tumors.
    Voena C; Peola S; Chiarle R
    Front Biosci (Schol Ed); 2015 Jun; 7(2):269-82. PubMed ID: 25961702
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation.
    Lee JK; Kim TM; Koh Y; Lee SH; Kim DW; Jeon YK; Chung DH; Yang SC; Kim YT; Kim YW; Heo DS; Bang YJ
    Lung Cancer; 2012 Aug; 77(2):460-3. PubMed ID: 22622260
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recent understanding of the molecular mechanisms for the efficacy and resistance of EGF receptor-specific tyrosine kinase inhibitors in non-small cell lung cancer.
    Nakata A; Gotoh N
    Expert Opin Ther Targets; 2012 Aug; 16(8):771-81. PubMed ID: 22762482
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.